Home  /  Resource Library  /  EHA 2019 | Anti-CD47 antibody, HU5F9-G4 with rituximab in relapsed/refractory diffuse large B-cell lymphoma and indolent non-Hodgkin lymphoma

EHA 2019 | Anti-CD47 antibody, HU5F9-G4 with rituximab in relapsed/refractory diffuse large B-cell lymphoma and indolent non-Hodgkin lymphoma

EHA 2019: Results of a phase Ib trial investigating CD47 immune checkpoint inhibitor Hu5F9-G4 combined with rituximab for B-cell lymphoma.